IGC Pharma Files 8-K on Security Holder Votes & Exhibits
Ticker: IGC · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1326205
| Field | Detail |
|---|---|
| Company | Igc Pharma, Inc. (IGC) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-event, filing, shareholder-vote
TL;DR
IGC Pharma filed an 8-K, expect shareholder votes and new exhibits soon.
AI Summary
IGC Pharma, Inc. filed an 8-K on October 14, 2025, reporting on events that occurred on October 10, 2025. The filing indicates a submission of matters to a vote of security holders, other events, and financial statements and exhibits. The company, formerly known as India Globalization Capital, Inc., is incorporated in Maryland and operates in the pharmaceutical preparations sector.
Why It Matters
This 8-K filing signals potential upcoming shareholder decisions and provides updated financial information, which could impact investor understanding of the company's direction and performance.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting on standard corporate events and does not appear to disclose any immediate material adverse information.
Key Players & Entities
- IGC Pharma, Inc. (company) — Registrant
- India Globalization Capital, Inc. (company) — Former company name
- October 10, 2025 (date) — Earliest event date
- October 14, 2025 (date) — Filing date
- Maryland (location) — State of incorporation
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What specific matters are being submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in the excerpt.
What are the 'Other Events' mentioned in the filing?
The filing lists 'Other Events' as a category, but the specific nature of these events is not detailed in the provided text.
When was IGC Pharma, Inc. formerly known as India Globalization Capital, Inc.?
The company's name was changed from India Globalization Capital, Inc. on May 5, 2005.
What is the Standard Industrial Classification (SIC) code for IGC Pharma, Inc.?
The SIC code for IGC Pharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the principal executive office address for IGC Pharma, Inc.?
The principal executive offices are located at 10224 Falls Road, Potomac, Maryland 20854.
Filing Stats: 870 words · 3 min read · ~3 pages · Grade level 10.4 · Accepted 2025-10-10 19:49:19
Filing Documents
- igc8k101025.htm (8-K) — 38KB
- igcex99-1.htm (EX-99.1) — 6KB
- image_001.jpg (GRAPHIC) — 5KB
- ex99-1_001.jpg (GRAPHIC) — 22KB
- 0001185185-25-001428.txt ( ) — 253KB
- igc-20251010.xsd (EX-101.SCH) — 3KB
- igc-20251010_lab.xml (EX-101.LAB) — 33KB
- igc-20251010_pre.xml (EX-101.PRE) — 22KB
- igc8k101025_htm.xml (XML) — 3KB
07 Submission of Matters
Item 5.07 Submission of Matters to a Vote of Security Holders. On October 10, 2025, IGC Pharma, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting the Company's stockholders (i) elected Mr. Ram Mukunda and Mr. James Moran to the Company's board of directors to serve as Class C directors until the 2028 annual meeting of Stockholders; (ii) ratified the appointment of Manohar Chowdhry & Associates as the Company's independent registered public accounting firm for the 2026 fiscal year; (iii) approved the grant of 5,000,000 shares of common stock to be granted from time to time to the Company's current and new employees, advisors, directors, and consultants by the board of directors, pursuant to certain metrics including performance, vesting, and incentive as set by the board of directors and or the CEO; and (iv) to effect an amendment to our Amended and Restated Articles of Incorporation to increase the authorized number of shares of our common stock from 150,000,000 shares to 600,000,000 shares of common stock; The total number of shares of the Company's common stock voted in person or by proxy at the Annual Meeting was 53,776,307 shares, representing approximately 59.22% of the 90,809,112 shares outstanding and entitled to vote at the Annual Meeting. We received a total of 18,341,638 broker non-votes. The director nominees were elected, and each matter submitted to a vote of the Company's stockholders at the Annual Meeting was approved by the requisite vote. The final voting results for each proposal that passed are set forth below. 1. Election of Directors. Nominee For Abstain Broker Non-votes Ram Mukunda 34,134,477 1,300,192 18,341,638 James Moran 34,917,233 517,436 18,341,638 2. Proposal to ratify the appointment of Manohar Chowdhry & Associates as the Company's independent registered public accounting firm for the 2026 fiscal year. For Against Abstain 53,213,920 236,934 325,4
01. Other Events
Item 8.01. Other Events. On October 10, 2025, IGC Pharma, Inc. held the Annual Meeting, as previously scheduled. All the proposals passed.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IGC PHARMA, INC. Dated: October 10, 2025 By: /s/ Claudia Grimaldi Name: Claudia Grimaldi Title: Principal Financial Officer and Vice President 3